<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Thyroid extract (desiccated thyroid): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Thyroid extract (desiccated thyroid): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Thyroid extract (desiccated thyroid): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10075" href="/d/html/10075.html" rel="external">see "Thyroid extract (desiccated thyroid): Drug information"</a> and <a class="drug drug_patient" data-topicid="11091" href="/d/html/11091.html" rel="external">see "Thyroid extract (desiccated thyroid): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708983"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Weight reduction:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Drugs with thyroid hormone activity, alone or with other therapeutic agents, have been used for the treatment of obesity. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F227348"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Adthyza;</li>
<li>Armour Thyroid;</li>
<li>Nature-Throid [DSC];</li>
<li>Niva Thyroid;</li>
<li>NP Thyroid;</li>
<li>Westhroid [DSC];</li>
<li>WP Thyroid [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F14851204"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Thyroid Product</span></li></ul></div>
<div class="block don drugH1Div" id="F53462606"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Doses presented as mg/kg/dose or mg/dose; closely review dosing units; adjust dose based upon clinical response and laboratory parameters. Tablet strengths may vary by manufacturer in terms of grains or mg; dosing recommendations are based on general clinical equivalencies that 1 grain = 60 mg or 65 mg; <sup>1</sup>/<sub>2</sub> grain = 30 mg or 32.5 mg; and <sup>1</sup>/<sub>4</sub> grain = 15 mg or 16.25 mg.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4d21da95-309f-429c-bde4-51d2cd4b7d94">Congenital hypothyroidism</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Congenital hypothyroidism:</b> Oral: 4.8 to 6 mg/kg/dose <b>or</b> 15 to 32.5 mg/dose once daily. <b>Note:</b> AAP recommends levothyroxine as the preferred treatment for hypothyroidism in neonates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16740880']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16740880'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F227359"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Doses presented as mg/kg/dose or mg/dose; closely review dosing units; adjust dose based upon clinical response and laboratory parameters. Tablet strengths may vary by manufacturer in terms of grains or mg; dosing recommendations are based on general clinical equivalencies that 1 grain = 60 mg or 65 mg; <sup>1</sup>/<sub>2</sub> grain = 30 mg or 32.5 mg; and <sup>1</sup>/<sub>4</sub> grain = 15 mg or 16.25 mg.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4d21da95-309f-429c-bde4-51d2cd4b7d94">Congenital hypothyroidism</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Congenital hypothyroidism: Note:</b> Guidelines do not recommend routine use of desiccated thyroid over levothyroxine monotherapy in the management of hypothyroidism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16740880','lexi-content-ref-25266247']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16740880','lexi-content-ref-25266247'])">Ref</a></span>). Infants should have therapy initiated at full doses; Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants 1 to 6 months: 4.8 to 6 mg/kg/dose <b>or</b> 15 to 32.5 mg/dose once daily</p>
<p style="text-indent:-2em;margin-left:4em;">Infants &gt;6 to 12 months: 3.6 to 4.8 mg/kg/dose <b>or</b> 30 to 48.75 mg/dose once daily</p>
<p style="text-indent:-2em;margin-left:4em;">Children 1 to 5 years: 3 to 3.6 mg/kg/dose <b>or</b> 45 to 65 mg/dose once daily</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to 12 years: 2.4 to 3 mg/kg/dose or 60 to 97.5 mg/dose once daily</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Typical doses 1.2 to 1.8 mg/kg/dose or &gt;90 mg/dose once daily</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51192739"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51192740"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F227351"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10075" href="/d/html/10075.html" rel="external">see "Thyroid extract (desiccated thyroid): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c90a631e-b4dd-4f5a-bbf9-599d632e2f7b">Hypothyroidism, primary</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypothyroidism, primary (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Current guidelines do not recommend desiccated thyroid for treatment of hypothyroidism (primary or secondary); levothyroxine monotherapy is preferred. Avoid use during pregnancy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25266247','lexi-content-ref-23246686','lexi-content-ref-27736313']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25266247','lexi-content-ref-23246686','lexi-content-ref-27736313'])">Ref</a></span>). Tablet strengths may vary by manufacturer in terms of grains or milligrams; dosing recommendations are based on general clinical equivalencies that 1 grain = 60 mg or 65 mg (depending on formulation).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 30 or 32.5 mg/day; in patients with cardiovascular disease or long-standing myxedema, initiate at 15 or 16.25 mg/day. May increase dose in 7.5 to 16.25 mg/day increments every 6 weeks if needed based on TSH levels; usual dose range: 60 to 130 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23539727','lexi-content-ref-34185829','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23539727','lexi-content-ref-34185829','lexi-content-ref-Manu.1'])">Ref</a></span>). Inadequate response to doses up to 180 or 195 mg/day may suggest missed doses or malabsorption.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990310"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987633"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F227327"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions are often indicative of excess thyroid replacement and/or hyperthyroidism.</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Abdominal cramps, alopecia, ataxia, cardiac arrhythmia, chest pain, constipation, diaphoresis, diarrhea, dyspnea, fever, headache, heat intolerance, increased appetite, insomnia, menstrual disease, myalgia, nervousness, palpitations, tachycardia, tremor, tremor of hands, vomiting, weight loss</p></div>
<div class="block coi drugH1Div" id="F227338"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to any component of the formulation; untreated thyrotoxicosis; uncorrected adrenal insufficiency</p></div>
<div class="block war drugH1Div" id="F227324"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal insufficiency: Use with caution in patients with adrenal insufficiency; symptoms may be exaggerated or aggravated; contraindicated in patients with uncorrected adrenal insufficiency. Treatment with glucocorticoids should precede thyroid replacement therapy in patients with adrenal insufficiency (ATA/AACE [Garber 2012]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use reduced initial dosage and conservative dose titration in patients with cardiovascular disease. Overtreatment may increase risk of adverse cardiovascular events, including angina and arrhythmia; patients with developing or worsening cardiac symptoms should have their dose reduced or therapy withheld for 7 days and then resumed at a reduced dose. Chronic untreated hypothyroidism predisposes patients to cardiovascular disease (ATA [Jonklaas 2014]; Razvi 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus and diabetes insipidus; symptoms may be exaggerated or aggravated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myxedema: Use with caution in patients with myxedema; symptoms may be exaggerated or aggravated; initial dosage reduction is recommended in patients with long-standing myxedema.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Desiccated thyroid: Contains variable amounts of T<sub>3</sub>, T<sub>4</sub>, and other triiodothyronine compounds which are more likely to cause cardiac signs or symptoms due to fluctuating thyroid hormone levels.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Infertility (unapproved use): Thyroid supplements are not recommended for the treatment of female or male infertility, unless associated with hypothyroidism.</p>
<p style="text-indent:-2em;margin-left:4em;">• Porcine derived: Some desiccated thyroid products are acquired from porcine thyroid glands of pigs processed for human food; production also occurs at a facility that handles bovine tissues from cows processed for human food. Contamination with porcine or bovine viruses, or other novel or unidentified viruses, is potentially a risk; however, there have been no reported cases of transmission of an infectious illness.</p>
<p style="text-indent:-2em;margin-left:4em;">• Weight reduction (unapproved use): <b>[US Boxed Warning]: In euthyroid patients, thyroid supplements within the range of daily hormonal requirements are ineffective for weight reduction. High doses may produce serious or even life-threatening toxic effects particularly when used with some anorectic drugs (eg, sympathomimetic amines).</b></p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878652"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Overtreatment may result in craniosynostosis in infants and premature closure of epiphyses in children; monitor use closely. May cause transient alopecia in children during the first few months of therapy. In neonates and infants, cardiac overload, arrhythmias, and aspiration from avid suckling may occur during initiation of therapy (eg, first 2 weeks); monitor closely. </p></div>
<div class="block foc drugH1Div" id="F227333"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adthyza: 15 mg, 16.25 mg, 30 mg, 32.5 mg, 60 mg, 65 mg, 90 mg, 97.5 mg, 120 mg, 130 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Armour Thyroid: 15 mg, 30 mg, 60 mg, 90 mg, 120 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Armour Thyroid: 180 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Armour Thyroid: 240 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Armour Thyroid: 300 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nature-Throid: 16.25 mg [DSC], 32.5 mg [DSC], 48.75 mg [DSC], 65 mg [DSC], 81.25 mg [DSC], 97.5 mg [DSC], 113.75 mg [DSC], 130 mg [DSC], 146.25 mg [DSC], 162.5 mg [DSC], 195 mg [DSC], 260 mg [DSC], 325 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Niva Thyroid: 15 mg, 30 mg, 60 mg, 90 mg, 120 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NP Thyroid: 15 mg, 30 mg, 60 mg, 90 mg, 120 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Westhroid: 32.5 mg [DSC], 65 mg [DSC], 97.5 mg [DSC], 130 mg [DSC], 195 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">WP Thyroid: 16.25 mg [DSC], 32.5 mg [DSC], 48.75 mg [DSC], 65 mg [DSC], 81.25 mg [DSC], 97.5 mg [DSC], 113.75 mg [DSC], 130 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 15 mg, 30 mg, 60 mg, 90 mg, 120 mg</p></div>
<div class="block geq drugH1Div" id="F227320"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F3422282"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Adthyza Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $0.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">16.25 mg (per each): $0.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $0.92</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">32.5 mg (per each): $0.92</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $1.02</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">65 mg (per each): $1.02</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">90 mg (per each): $1.60</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">97.5 mg (per each): $1.60</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $1.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">130 mg (per each): $1.87</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Armour Thyroid Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $0.98</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $1.16</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $1.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">90 mg (per each): $2.01</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $2.35</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">180 mg (per each): $1.76</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">240 mg (per each): $2.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $2.52</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (NP Thyroid Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $0.89</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $1.05</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $1.16</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">90 mg (per each): $1.82</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $2.13</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Thyroid Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $0.85</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $1.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $1.11</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">90 mg (per each): $1.73</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $2.03</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868408"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 30 mg, 60 mg, 125 mg</p></div>
<div class="block adip drugH1Div" id="F53568832"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">For purposes of conversion, levothyroxine sodium (T<sub>4</sub>) 100 mcg is usually considered equivalent to desiccated thyroid 60 to 65 mg (1 grain), thyroglobulin 60 to 65 mg (1 grain), or liothyronine sodium (T<sub>3</sub>) 25 mcg (Cytomel Prescribing Information 2016). However, these are rough guidelines only and do not obviate the careful re-evaluation of a patient when switching thyroid hormone preparations, including a change from one brand of levothyroxine to another.</p></div>
<div class="block admp drugH1Div" id="F52613925"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer on an empty stomach (eg, 30 to 60 minutes before breakfast) to increase absorption.</p></div>
<div class="block adm drugH1Div" id="F9626657"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer on an empty stomach (eg, 30 to 60 minutes prior to breakfast) to increase absorption.</p></div>
<div class="block sts drugH1Div" id="F25226398"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 15°C to 30°C (59°F to 86°F). </p></div>
<div class="block usep drugH1Div" id="F53569103"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Replacement or supplemental therapy in hypothyroidism of any etiology (FDA approved in all ages); pituitary TSH suppressant for the treatment or prevention of various types of euthyroid goiter, thyroid nodules, thyroiditis, multinodular goiter, and thyroid cancer (FDA approved in adults); <b>Note:</b> Not indicated for treatment of transient hypothyroidism associated with subacute thyroiditis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Clinical practice guidelines do not recommend routine use of desiccated thyroid over levothyroxine monotherapy in the management of hypothyroidism (AAP 2006; ATA [Jonklaas 2014]) or for TSH suppression in the management in thyroid cancer (ATA [Haugen 2015]). Guidelines do not recommend using TSH suppression for benign thyroid nodules in iodine sufficient patients (ATA [Haugen 2015]).</p></div>
<div class="block mst drugH1Div" id="F9954591"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Desiccated thyroid is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to concerns for cardiac effects; safer alternatives are available (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300136"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F227329"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Amezinium: Thyroid Products may enhance the stimulatory effect of Amezinium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the absorption of Thyroid Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apalutamide: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the serum concentration of Thyroid Products. Management: Administer oral thyroid products at least 4 hours prior to or one hour after bile acid sequestrants, or monitor for decreased serum concentrations and clinical effects of oral thyroid products during coadministration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Polystyrene Sulfonate: May decrease the serum concentration of Thyroid Products. Management: Consider administering thyroid products at least 4 hours prior to calcium polystyrene sulfonate. Monitor for signs and symptoms of hypothyroidism with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Salts: May diminish the therapeutic effect of Thyroid Products. Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: May decrease the serum concentration of Thyroid Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Thyroid Products may decrease the serum concentration of Cardiac Glycosides. Specifically, returning to a euthyroid state from a hypothyroid state may decrease the serum concentration of cardiac glycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ciprofloxacin (Systemic): May decrease the serum concentration of Thyroid Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin: May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Furosemide: May decrease the protein binding of Thyroid Products. This may lead to a transient increase in free thyroid hormone concentrations and to a later decrease in total thyroid hormone concentrations.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lanthanum: May decrease the serum concentration of Thyroid Products. Management: Separate the administration of thyroid products and lanthanum by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PHENobarbital: May decrease the serum concentration of Thyroid Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenytoin: May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piracetam: May enhance the adverse/toxic effect of Thyroid Products. Specifically, symptoms including confusion, irritability, and sleep disorder have been described during concomitant use.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Primidone: May decrease the serum concentration of Thyroid Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease the serum concentration of Thyroid Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May diminish the therapeutic effect of Thyroid Products. Thyroid product dose requirements may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Iodide I131: Thyroid Products may diminish the therapeutic effect of Sodium Iodide I131.  Management: Discontinue thyroid products before sodium iodide I-131 administration, and avoid concurrent use. Stop triiodothyronine (T3) 2 weeks before, and stop thyroxine (T4) 4 weeks before, sodium iodide I-131 administration.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Polystyrene Sulfonate: May decrease the serum concentration of Thyroid Products. Management: Consider administering thyroid products at least 4 hours prior to sodium polystyrene sulfonate. Monitor for signs and symptoms of hypothyroidism with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Somatropin: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Soybean: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Thyroid Products may increase the metabolism of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: Thyroid Products may enhance the arrhythmogenic effect of Tricyclic Antidepressants. Thyroid Products may enhance the stimulatory effect of Tricyclic Antidepressants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Thyroid Products may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53623817"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Overt hypothyroidism increases the risk of irregular menses and infertility; thyroid replacement is recommended to normalize thyroid function in infertile patients with overt hypothyroidism who desire to become pregnant. Thyroid replacement may also be used in infertile patients with subclinical hypothyroidism using assisted reproductive techniques to become pregnant; however, desiccated thyroid is not the preferred thyroid replacement agent (ATA [Alexander 2017]).</p></div>
<div class="block pri drugH1Div" id="F12966353"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Endogenous thyroid hormones minimally cross the placenta. Desiccated thyroid has not been found to adversely affect the fetus following maternal use during pregnancy; however, normal levels of maternal thyroid hormones are required for fetal development. Untreated maternal hypothyroidism can be associated with adverse effects in both the mother and fetus, including spontaneous abortion, stillbirth, premature birth, low birth weight, impaired neurocognitive development in the offspring, abruptio placentae, gestational hypertension, and preeclampsia (ACOG 2020; ATA [Alexander 2017]).</p>
<p style="text-indent:0em;margin-top:2em;">Thyroid replacement therapy minimizes the risk of adverse pregnancy outcomes in patients with overt hypothyroidism and treatment is recommended for all patients with overt hypothyroidism during pregnancy (ACOG 2020; ATA [Alexander 2017]); however, maternal supplementation with desiccated thyroid does not provide the fetus with sufficient concentrations of T4 required for the developing fetal brain. Therefore, desiccated thyroid is not the preferred treatment of maternal hypothyroidism and should not be used in pregnant patients (ACOG 2020; ATA [Alexander 2017]).</p>
<p style="text-indent:0em;margin-top:2em;">Due to alterations of endogenous maternal thyroid hormones, hypothyroid patients treated with a thyroid replacement product prior to pregnancy require a dose increase as soon as pregnancy is confirmed (ATA [Alexander 2017]). Close monitoring of pregnant patients is recommended (ATA [Alexander 2017]).</p></div>
<div class="block mopp drugH1Div" id="F53569104"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">T<sub>4</sub>, TSH, heart rate, blood pressure, clinical signs of hypo- and hyperthyroidism; growth, bone development (children); TSH is the most reliable guide for evaluating adequacy of thyroid replacement dosage. TSH may be elevated during the first few months of thyroid replacement despite patients being clinically euthyroid. In cases where T<sub>4</sub> remains low and TSH is within normal limits, an evaluation of "free" (unbound) T<sub>4</sub> is needed to evaluate further increase in dosage. Free T<sub>4</sub> (not TSH) should be monitored to guide treatment in patients with central hypothyroidism (ATA [Jonklaas 2014]).</p>
<p style="text-indent:0em;margin-top:2em;">In congenital hypothyroidism, adequacy of replacement should be determined using both TSH and total- or free-T<sub>4</sub>. During the first 3 years of life, total- or free-T<sub>4</sub> should be maintained in the upper <sup>1</sup>/<sub>2</sub> of the normal range; this should result in normalization of the TSH. In some patients, TSH may not normalize due to a resetting of the pituitary-thyroid feedback as a result of in utero hypothyroidism. Monitor closely for cardiac overload, arrhythmias and aspiration from avid suckling.</p>
<p style="text-indent:0em;margin-top:2em;">Pediatric patients: Monitor closely for under/overtreatment. Undertreatment may decrease intellectual development and linear growth, and lead to poor school performance due to impaired concentration and slowed mentation. Overtreatment may adversely affect brain maturation, accelerate bone age (leading to premature closure of the epiphyses and reduced adult height); craniosynostosis has been reported in infants. Perform routine clinical examinations at regular intervals (to assess mental and physical growth and development). Treated children may experience a period of catch-up growth. Monitor TSH and total or free T<sub>4</sub> at 2 and 4 weeks after starting treatment, every 1 to 2 months during the first year of life, every 2 to 3 months between ages 1 to 3 years, and every 3 to 12 months thereafter until growth is completed (AAP 2006; ATA [Jonklaas 2014]); repeat tests 2 weeks after any change in dosage.</p>
<p style="text-indent:0em;margin-top:2em;">Adults: TSH 4 to 6 weeks after treatment initiation or dose changes, 4 to 6 months after adequate replacement dose determined, followed by every 12 months thereafter (or more frequently depending on clinical situation) (ATA [Jonklaas 2014]).</p></div>
<div class="block rerp drugH1Div" id="F53568847"><span class="drugH1">Reference Range</span>
<table border="1" frame="border" rules="all">
<caption>Thyroid Function Tests</caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">Lab Parameters</p></th>
<th align="center">
<p style="text-indent:0em;">Age</p></th>
<th align="center">
<p style="text-indent:0em;">Normal Range</p></th></tr></thead>
<tbody>
<tr>
<td align="center" rowspan="4">
<p style="text-indent:0em;">T<sub>4</sub> (thyroxine) serum concentration</p></td>
<td align="center">
<p style="text-indent:0em;">1-7 days</p></td>
<td align="center">
<p style="text-indent:0em;">10.1-20.9 mcg/dL</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">8-14 days </p></td>
<td align="center">
<p style="text-indent:0em;">9.8-16.6 mcg/dL </p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">1 month to 1 year </p></td>
<td align="center">
<p style="text-indent:0em;">5.5-16.0 mcg/dL</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;1 year </p></td>
<td align="center">
<p style="text-indent:0em;">4.0-12.0 mcg/dL </p></td></tr>
<tr>
<td align="center" rowspan="6">
<p style="text-indent:0em;">Free thyroxine index (FTI) </p></td>
<td align="center">
<p style="text-indent:0em;">1-3 days</p></td>
<td align="center">
<p style="text-indent:0em;">9.3-26.6 </p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">1-4 weeks </p></td>
<td align="center">
<p style="text-indent:0em;">7.6-20.8 </p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">1-4 months </p></td>
<td align="center">
<p style="text-indent:0em;">7.4-17.9 </p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">4-12 months </p></td>
<td align="center">
<p style="text-indent:0em;">5.1-14.5 </p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">1-6 years </p></td>
<td align="center">
<p style="text-indent:0em;">5.7-13.3 </p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;6 years </p></td>
<td align="center">
<p style="text-indent:0em;">4.8-14.0  </p></td></tr>
<tr>
<td align="center" rowspan="4">
<p style="text-indent:0em;">T<sub>3</sub> serum concentration</p></td>
<td align="center">
<p style="text-indent:0em;">Newborns</p></td>
<td align="center">
<p style="text-indent:0em;">100-470 ng/dL</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">1-5 years </p></td>
<td align="center">
<p style="text-indent:0em;">100-260 ng/dL </p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">5-10 years </p></td>
<td align="center">
<p style="text-indent:0em;">90-240 ng/dL </p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">10 years to Adult </p></td>
<td align="center">
<p style="text-indent:0em;">70-210 ng/dL </p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">T<sub>3</sub> uptake</p></td>
<td align="center"></td>
<td align="center">
<p style="text-indent:0em;">35%-45% </p></td></tr>
<tr>
<td align="center" rowspan="4">
<p style="text-indent:0em;">TSH serum concentration</p></td>
<td align="center">
<p style="text-indent:0em;">Cord</p></td>
<td align="center">
<p style="text-indent:0em;">3-22 micro international units/mL </p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">1-3 days </p></td>
<td align="center">
<p style="text-indent:0em;">&lt;40 micro international units/mL </p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">3-7 days </p></td>
<td align="center">
<p style="text-indent:0em;">&lt;25 micro international units/mL </p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;7 days </p></td>
<td align="center">
<p style="text-indent:0em;">0-10 micro international units/mL </p></td></tr></tbody></table>
</div>
<div class="block pha drugH1Div" id="F227323"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">The primary active compound is T<sub>3</sub> (triiodothyronine), which may be converted from T<sub>4</sub> (thyroxine) and then circulates throughout the body to influence growth and maturation of various tissues; exact mechanism of action is unknown; however, it is believed the thyroid hormone exerts its many metabolic effects through control of DNA transcription and protein synthesis; involved in normal metabolism, growth, and development; promotes gluconeogenesis, increases utilization and mobilization of glycogen stores and stimulates protein synthesis, increases basal metabolic rate</p></div>
<div class="block phk drugH1Div" id="F227337"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Liothyronine (T<sub>3</sub>): ~3 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Thyroxine (T<sub>4</sub>): 40% to 80%; T<sub>3</sub>: 95%; desiccated thyroid contains T<sub>4</sub>, T<sub>3</sub>, and iodine (primarily bound)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: T<sub>4</sub>: &gt;99% bound to plasma proteins including thyroxine-binding globulin, thyroxine-binding prealbumin, and albumin</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic to triiodothyronine (active); ~80% T<sub>4</sub> deiodinated in kidney and periphery; glucuronidation/conjugation also occurs; undergoes enterohepatic recirculation </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">T<sub>4</sub>: Euthyroid: 6 to 7 days; Hyperthyroid: 3 to 4 days; Hypothyroid: 9 to 10 days</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">T<sub>3</sub>: 0.75 days (Brent, 2011)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak: Serum: T<sub>4</sub>: 2 to 4 hours; T<sub>3</sub>: 2 to 3 days</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (major route of elimination); partially feces</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F56520254"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Thyreoidea siccata</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Thyreoidin | Thyreoidinum</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Erfa thyroid</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Armour thyroid</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Cinetic</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Neytabs thymum</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Thyreoid glostrup | Thyroid naf | Wp thyroid</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Armour thyroid</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Armour thyroid</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Tiroida</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Thiramyn | Thyreoidin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Thyrodin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Thyreoidin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Tiroidina</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thyroid-extract-desiccated-thyroid-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Adthyza.1">
<a name="Adthyza.1"></a>Adthyza (thyroid tablets, USP) [prescribing information]. Woburn, MA: Azurity Pharmaceuticals Inc; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28056690">
<a name="28056690"></a>Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. <i>Thyroid</i>. 2017;27(3):315-389. doi:10.1089/thy.2016.0457<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thyroid-extract-desiccated-thyroid-pediatric-drug-information/abstract-text/28056690/pubmed" id="28056690" target="_blank">28056690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16740880">
<a name="16740880"></a>American Academy of Pediatrics, Section on Endocrinology and Committee on Genetics, American Thyroid Association, et al. Update of Newborn Screening and Therapy for Congenital Hypothyroidism. <i>Pediatrics</i>,. 2006;117(6):2290-303.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thyroid-extract-desiccated-thyroid-pediatric-drug-information/abstract-text/16740880/pubmed" id="16740880" target="_blank">16740880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32443080">
<a name="32443080"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 223: Thyroid disease in pregnancy. <i>Obstet Gynecol</i>. 2020;135(6):e261-e274. doi:10.1097/AOG.0000000000003893<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thyroid-extract-desiccated-thyroid-pediatric-drug-information/abstract-text/32443080/pubmed" id="32443080" target="_blank">32443080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ArmourThyroid.1">
<a name="ArmourThyroid.1"></a>Armour Thyroid (thyroid tablet) [prescribing information]. Madison, NJ: Allergan; June 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baskin.1">
<a name="Baskin.1"></a>Baskin HJ, Cobin RH, Duick DS, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hyperthyroidism and Hypothyroidism. <i>Endocr Pract</i>. 2002;8(6):457-469.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7304660">
<a name="7304660"></a>Bhasin S, Wallace W, Lawrence JB, et al. Sudden Death Associated With Thyroid Hormone Abuse. <i>Am J Med</i>. 1981;71(5):887-890.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thyroid-extract-desiccated-thyroid-pediatric-drug-information/abstract-text/7304660/pubmed" id="7304660" target="_blank">7304660</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brent.1">
<a name="Brent.1"></a>Brent GA, Koenig RJ. Chapter 39. Thyroid and Anti-Thyroid Drugs. In: Brunton LL, Chabner BA, Knollmann BC, eds. <i>Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics</i>. 12th ed. McGraw-Hill Medical; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cytomel.1">
<a name="Cytomel.1"></a>Cytomel (liothyronine sodium) [prescribing information]. New York, NY: Pfizer; June 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27736313">
<a name="27736313"></a>Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(11):3888-3921. doi:10.1210/jc.2016-2118<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thyroid-extract-desiccated-thyroid-pediatric-drug-information/abstract-text/27736313/pubmed" id="27736313" target="_blank">27736313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23246686">
<a name="23246686"></a>Garber KR, Cobin RH, Gharib H, et al; American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. <i>Endocr Pract</i>. 2012;18(6):988-1028.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thyroid-extract-desiccated-thyroid-pediatric-drug-information/abstract-text/23246686/pubmed" id="23246686" target="_blank">23246686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27167915">
<a name="27167915"></a>Gharib H, Papini E, Garber JR, et al; AACE/ACE/AME Task Force on Thyroid Nodules. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules--2016 update. <i>Endocr Pract.</i> 2016;22(5):622-639. doi:10.4158/EP161208.GL<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thyroid-extract-desiccated-thyroid-pediatric-drug-information/abstract-text/27167915/pubmed" id="27167915" target="_blank">27167915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26462967">
<a name="26462967"></a>Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. <i>Thyroid</i>. 2016;26(1):1-133. doi:10.1089/thy.2015.0020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thyroid-extract-desiccated-thyroid-pediatric-drug-information/abstract-text/26462967/pubmed" id="26462967" target="_blank">26462967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2143640">
<a name="2143640"></a>Helfand M, Crapo LM. Monitoring Therapy in Patients Taking Levothyroxine. <i>Ann Intern Med</i>. 1990;113(6):450-454.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thyroid-extract-desiccated-thyroid-pediatric-drug-information/abstract-text/2143640/pubmed" id="2143640" target="_blank">2143640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23539727">
<a name="23539727"></a>Hoang TD, Olsen CH, Mai VQ, Clyde PW, Shakir MK. Desiccated thyroid extract compared with levothyroxine in the treatment of hypothyroidism: a randomized, double-blind, crossover study. <i>J Clin Endocrinol Metab</i>. 2013;98(5):1982-1990. doi:10.1210/jc.2012-4107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thyroid-extract-desiccated-thyroid-pediatric-drug-information/abstract-text/23539727/pubmed" id="23539727" target="_blank">23539727</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Johnson.1">
<a name="Johnson.1"></a>Johnson DG, Campbell S. Hormonal and Metabolic Agents. In: Bressler R, Katz MD, eds. <i>Geriatric Pharmacology</i>. McGraw-Hill; 1993:427-450.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25266247">
<a name="25266247"></a>Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. <i>Thyroid</i>. 2014;24(12):1670-1751. doi:10.1089/thy.2014.0028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thyroid-extract-desiccated-thyroid-pediatric-drug-information/abstract-text/25266247/pubmed" id="25266247" target="_blank">25266247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nature-Throid.1">
<a name="Nature-Throid.1"></a>Nature-Throid (thyroid USP) tablets [prescribing information]. Cave Creek, AZ: RLC Labs; received July 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nature-Throid.2">
<a name="Nature-Throid.2"></a>Nature-Throid (thyroid USP) tablets [prescribing information]. Cave Creek, AZ: RLC Labs; April 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NPThyroid.1">
<a name="NPThyroid.1"></a>NP Thyroid (thyroid USP) tablets [prescribing information]. Alpharetta, GA: Acella Pharmaceuticals LLC; October 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24783053">
<a name="24783053"></a>Pearce SH, Brabant G, Duntas LH, et al. 2013 ETA Guideline: Management of subclinical hypothyroidism. <i>Eur Thyroid J</i>. 2013;2(4):215-228. doi:10.1159/000356507<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thyroid-extract-desiccated-thyroid-pediatric-drug-information/abstract-text/24783053/pubmed" id="24783053" target="_blank">24783053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29673469">
<a name="29673469"></a>Razvi S, Jabbar A, Pingitore A, et al. Thyroid hormones and cardiovascular function and diseases. <i>J Am Coll Cardiol</i>. 2018;71(16):1781‐1796. doi:10.1016/j.jacc.2018.02.045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thyroid-extract-desiccated-thyroid-pediatric-drug-information/abstract-text/29673469/pubmed" id="29673469" target="_blank">29673469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sanders.1">
<a name="Sanders.1"></a>Sanders LR. Pituitary, Thyroid, Adrenal and Parathyroid Diseases in the Elderly. <i>Geriatric Medicine</i>. 1990;475-487.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2709545">
<a name="2709545"></a>Sawin CT, Geller A, Hershman JM, et al. The Aging Thyroid. The Use of Thyroid Hormone in Older Persons. <i>JAMA</i>. 1989;261(18):2653-2655.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thyroid-extract-desiccated-thyroid-pediatric-drug-information/abstract-text/2709545/pubmed" id="2709545" target="_blank">2709545</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34185829">
<a name="34185829"></a>Shakir MKM, Brooks DI, McAninch EA, et al. Comparative effectiveness of levothyroxine, desiccated thyroid extract, and levothyroxine+liothyronine in hypothyroidism. <i>J Clin Endocrinol Metab</i>. 2021;106(11):e4400-e4413. doi:10.1210/clinem/dgab478<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thyroid-extract-desiccated-thyroid-pediatric-drug-information/abstract-text/34185829/pubmed" id="34185829" target="_blank">34185829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2644903">
<a name="2644903"></a>Watts NB. Use of a Sensitive Thyrotropin Assay for Monitoring Treatment With Levothyroxine. <i>Arch Intern Med</i>. 1989;149(2):309-312.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thyroid-extract-desiccated-thyroid-pediatric-drug-information/abstract-text/2644903/pubmed" id="2644903" target="_blank">2644903</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 86692 Version 248.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
